tiprankstipranks
TipRanksTop Financial ExpertsInsidersNew Enterprise Associates 14, L.P.

New Enterprise Associates 14, L.P. Insider Profile

4 Followers
New Enterprise Associates 14, L.P., Ten Percent Owner at TRACON Pharmaceuticals, holds 0.00 shares in Oyster Point Pharma (Ticker: OYST), holds 2.61M shares in IMARA (Ticker: IMRA), holds 5.96M shares in Mersana Therapeutics (Ticker: MRSN).
tipranks
New Enterprise Associates 14, L.P.

New Enterprise Associates 14, L.P.
TRACON Pharmaceuticals (TCON)
Ten Percent Owner

Ranked #99,480 out of 100,689 Corporate Insiders

Profitable Transactions

15%
4 out of 26 Profitable Transactions

Average Return

-52.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$208M
66.77%
16.45%
4.96%
3.65%
8.17% Others
A breakdown of New Enterprise Associates 14, L.P.'s holdings

Insider Roles

Adaptimmune Therapeutics
(ADAP)
Ten Percent Owner
Mersana Therapeutics
(MRSN)
Ten Percent Owner
IMARA
(IMRA)
Ten Percent Owner
Champions Oncology
(CSBR)
Ten Percent Owner
+6 other positions
Roles that New Enterprise Associates 14, L.P. holds in companies

Most Profitable Insider Trade

Stock:
Adaptimmune Therapeutics
(ADAP)
Rating:Informative Buy
Date:Mar 28, 2017 - Mar 28, 2018
Return:+128.10%
The most profitable trade made by New Enterprise Associates 14, L.P.

New Enterprise Associates 14, L.P.'s Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
TRACON Pharmaceuticals
Mar 27, 2018
Ten Percent Owner
Informative Buy
1.91M
$5.03M
Adaptimmune Therapeutics
Sep 10, 2018
Ten Percent Owner
Informative Buy
4.98M
$138.57M
Appian
Feb 15, 2018
Ten Percent Owner
Uninformative Buy
$0.00
Synlogic
Jan 26, 2018
Ten Percent Owner
Uninformative Buy
4.00M
$3.13M
Surface Oncology
May 22, 2020
Ten Percent Owner
Informative Sell
1.53M
$2.36M
MULE
Mulesoft Inc
May 09, 2018
Uninformative Sell
$0.00
Mersana Therapeutics
Sep 16, 2020
Ten Percent Owner
Uninformative Sell
$34.15M
Galera Therapeutics
Nov 12, 2019
Ten Percent Owner
Uninformative Buy
$6.45M
Oyster Point Pharma
Jan 04, 2023
Ten Percent Owner
Uninformative Sell
$0.00
CSPR
Casper Sleep
Feb 12, 2020
Informative Buy
15.00M
$42.19M
Champions Oncology
Mar 10, 2020
Ten Percent Owner
Uninformative Sell
4.95M
$7.57M
IMARA
Apr 07, 2022
Ten Percent Owner
Informative Sell
746.44K
$10.29M
LOXO
Loxo Oncology
Aug 06, 2014
Informative Buy
3.00M
$419.91M
List of latest transactions for each holding click on a transaction to see New Enterprise Associates 14, L.P.'s performance on stock

New Enterprise Associates 14, L.P. insider profile FAQ

What is the percentage of profitable transactions made by New Enterprise Associates 14, L.P.?
The percentage of profitable transactions made by New Enterprise Associates 14, L.P. is 15%.
    What is the average return per transaction made by New Enterprise Associates 14, L.P.?
    The average return per transaction made by New Enterprise Associates 14, L.P. is -52.10%.
      What stocks does New Enterprise Associates 14, L.P. hold?
      New Enterprise Associates 14, L.P. holds: TCON, ADAP, APPN, SYBX, SURF, MULE, MRSN, GRTX, OYST, CSPR, CSBR, IMRA, LOXO stocks.
        What was New Enterprise Associates 14, L.P.’s latest transaction?
        New Enterprise Associates 14, L.P. latest transaction was an Uninformative Sell of ―.
          What was New Enterprise Associates 14, L.P.'s most profitable transaction?
          New Enterprise Associates 14, L.P.’s most profitable transaction was an Informative Buy of ADAP stock on March 28, 2017. The return on the trade was 128.10%.
            What is New Enterprise Associates 14, L.P.'s role in TRACON Pharmaceuticals?
            New Enterprise Associates 14, L.P.'s role in TRACON Pharmaceuticals is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.